Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P08908 (
5-HT1A
)
5,574
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The serotonin
5-HT1A
and 5-HT1B receptors are two structurally related but pharmacologically distinguishable 5-HT receptor types. In brain, the
5-HT1A
receptor is localized on the soma and dendrites of neurons, whereas the 5-HT1B receptor is targeted to the axon terminals. We previously showed that these two receptors are targeted in different membrane compartments when stably expressed in the epithelial LLC-
PK1
cell line. Further investigations on the mechanisms responsible for their differential targeting were done by constructing chimeras of
5-HT1A
and 5-HT1B receptors still able to bind specifically [3H]lysergic acid diethylamide and selective agonists and antagonists. Their cellular localization examined by confocal microscopy suggests that the third intracellular domain of the 5-HT1B receptor was responsible for its Golgi-like localization in transfected LLC-
PK1
cells. In contrast, the third intracellular domain of the
5-HT1A
receptor apparently allowed the sorting of the chimeras to the plasma membrane. Further inclusion of the C-terminal domain of the
5-HT1A
receptor in their sequence led to a basolateral localization, whereas that of the 5-HT1B receptor allowed an apical targeting, suggesting the existence of a targeting signal in this portion of the receptor(s).
...
PMID:Differential membrane targeting and pharmacological characterization of chimeras of rat serotonin 5-HT1A and 5-HT1B receptors expressed in epithelial LLC-PK1 cells. 983 27
The efficiency of antisense approaches to produce a selective regional inhibition of the expression of brain
5-HT1A
receptors was tested in the rat. In vivo ICV injections of modified antisense oligodesoxynucleotides yielded at most an 18% specific decrease in
5-HT1A
receptor expression in the hippocampus only, as measured by [3H]8-OH-DPAT autoradiographic labeling. In vitro, when
5-HT1A
receptors were transiently expressed in LLC-
PK1
cells, co-transfection with antisense RNA encoding plasmids resulted in a marked reduction (50-70%) in the density of
5-HT1A
binding sites. In vivo stereotaxic injections of the same constructs into the hippocampus, but not in the raphe, which contains
5-HT1A
autoreceptors, were shown to produce a approximately 20% reduction in local
5-HT1A
receptor density. These data show that antisense strategies could be used to inhibit
5-HT1A
receptors expression in the rat hippocampus, but with a limited efficacy.
...
PMID:Limited inhibition of 5-HT1A receptor expression in the rat brain by antisense RNA and oligodesoxynucleotides. 1002 90